Overview

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Status:
NOT_YET_RECRUITING
Trial end date:
2028-07-13
Target enrollment:
Participant gender:
Summary
This study is researching a particular group of experimental drugs administered for a short period in the treatment of patients with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Phase:
PHASE1
Details
Lead Sponsor:
Regeneron Pharmaceuticals